Detalles de la búsqueda
1.
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Proc Natl Acad Sci U S A
; 121(17): e2321898121, 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38625939
2.
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Gynecol Oncol
; 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38493021
3.
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
Gynecol Oncol
; 187: 12-20, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38703673
4.
Novel FOXL2 Mutation in an Ovarian Adult Granulosa Cell Tumor: Report of a Case With Diagnostic and Clinicopathologic Implications.
Int J Gynecol Pathol
; 2024 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38426544
5.
Integrated mutational landscape analysis of uterine leiomyosarcomas.
Proc Natl Acad Sci U S A
; 118(15)2021 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33876771
6.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Ann Surg Oncol
; 30(9): 5597-5609, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358686
7.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol
; 168: 157-165, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36442427
8.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol
; 170: 38-45, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610380
9.
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
Gynecol Oncol
; 170: 11-18, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36608382
10.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol
; 170: 172-178, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706643
11.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol
; 169: 98-105, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525930
12.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Gynecol Oncol
; 172: 65-71, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958197
13.
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Cancer
; 128(6): 1206-1218, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34875107
14.
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Br J Cancer
; 126(12): 1695-1703, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35149854
15.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Gynecol Oncol
; 166(2): 351-357, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641325
16.
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol
; 166(1): 117-125, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35599167
17.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Proc Natl Acad Sci U S A
; 116(2): 619-624, 2019 01 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30584090
18.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Proc Natl Acad Sci U S A
; 116(45): 22730-22736, 2019 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31624127
19.
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Gynecol Oncol
; 163(3): 557-562, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34602287
20.
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
Gynecol Oncol
; 163(1): 93-99, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34372971